Sean H Lim

10PUBLICATIONS
57CO-AUTHORS
Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 17, 2026
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

|Dec 20, 2025
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.

Marcus A Widdess, Anastasia Pakidi, Hannah J Metcalfe

|Sep 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

Kirstie L S Cleary, Monika Semmrich, Linda Martensson

|Sep 08, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli

|Dec 28, 2023
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges.

Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani

|Mar 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.

Sean H Lim, Beth Stuart, Debora Joseph-Pietras

Pageof 2

Frequent Collaborators

7 joint publications

Mark S Cragg

5 joint publications

Stephen A Beers

3 joint publications

Aymen Al-Shamkhani

2 joint publications

Peter W M Johnson